Enzo Biochem, Inc.
 (ENZ)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Tue, Jan. 26, 9:14 AM
    • Enzo Biochem (NYSE:ENZ) receives the $7M from PerkinElmer (NYSE:PKI) that settled its breach of contract and patent infringement suit related to PerkinElmer's unauthorized distribution of Enzo's nucleotide labeling technologies for clinical use.
    • Previously: Enzo settles suit with PerkinElmer (June 23, 2014)
    | Tue, Jan. 26, 9:14 AM
  • Wed, Jan. 6, 10:23 AM
    • Agilent Technologies (A -0.2%) will pay Enzo Biochem (ENZ -1.1%) $9M to settle an infringement suit related to Enzo's U.S. Patent No. 7,064,197, the third resolution of 11 brought by Enzo against different companies. Eight cases remain pending.
    • The patent pertains to technology used in nucleic acid detection.
    | Wed, Jan. 6, 10:23 AM
  • Dec. 30, 2015, 9:23 AM
    | Dec. 30, 2015, 9:23 AM
  • Dec. 29, 2015, 10:09 AM
    • The opposing sides of proxy fight over the election of two directors at Enzo Biochem (ENZ +1.8%) has ratcheted up a notch ahead of the company's annual meeting on January 6. Activist investor Lone Star Value Management is backing two candidates that it believes are more shareholder-friendly and will back initiatives that could unlock value in the firm. Management lacks enthusiasm for Lone Star's picks so it is backing different candidates.
    • Yesterday afternoon, the company issued a press release stating that institutional proxy advisors ISS and Glass Lewis recommend that shareholders vote for the incumbent nominees, Gregory Bortz and Dov Perlysky, stating that the dissidents (Lone Star) have not made a compelling case that change is necessary.
    • This morning, Lone Star published its own press release stating its disappointment with the advisory firms' positions, perceiving their reports as mistake-ridden based on flawed logic. It believes its nominees, Dimitrios Angelis and John Climaco, will be advocates for change and better corporate governance.
    • Previously: Enzo Biochem annual meeting approaches; shareholders to vote on control by activist investor (Dec. 22)
    | Dec. 29, 2015, 10:09 AM
  • Dec. 22, 2015, 1:23 PM
    • Thinly traded micro cap Enzo Biochem (ENZ -1.5%) will hold its annual meeting of shareholders on January 6. On the docket is a vote on directors backed by activist investor Lone Star Value, who believes new leadership is needed to unlock the full value of the firm. Unsurprisingly, Enzo management takes a dim view of the matter and urges shareholders to vote against the proposal.
    • Shares have doubled since late May but are only up 3% for the year.
    | Dec. 22, 2015, 1:23 PM
  • Dec. 8, 2015, 7:43 AM
    • Enzo Biochem (ENZ -0.2%) FQ1 results: Revenues: $25.2M (+1.6%); Gross Profit: $11.2M (+1.8%); Net Income: $4.4M (-218.9%); EPS: $0.10 (+225.0%); Non-GAAP Loss Per Share: ($0.05) (+37.5%%); Quick Assets: $30.6M (69.1%).
    • No guidance given.
    | Dec. 8, 2015, 7:43 AM
  • Dec. 7, 2015, 4:27 PM
    • Enzo Biochem (NYSE:ENZ): FQ1 EPS of -$0.05 in-line.
    • Revenue of $25.17M (+1.4% Y/Y) beats by $0.17M.
    • Press Release
    | Dec. 7, 2015, 4:27 PM
  • Oct. 13, 2015, 10:30 AM
    • Enzo Biochem (ENZ +3.8%) settles its infringement case over its U.S. Patent No. 7,064,197 with Affymetrix by agreeing to a $10M payment from Affymetrix. Nine other infringement lawsuits over the same patent remain pending.
    • The patent is titled, "System, array and non-porous solid support comprising fixed or immobilized nucleic acids."
    | Oct. 13, 2015, 10:30 AM
  • Oct. 13, 2015, 7:52 AM
    • Enzo Biochem (ENZ -0.5%) FQ4 results: Revenues: $25.7M (+3.2%); Gross Profit: $11.3M (+3.7%); Net Income: $8.4M (+362.5%); EPS: $0.18 (+357.1%).
    • FY2015 results: Revenues: $97.6M (+1.8%); Gross Profit: $42.8M (+2.6%); Net Loss: ($2.3M) (+77.0%); Loss Per Share: ($0.05) (+78.3%); Quick Assets: $18.1M (+3.4%).
    • No guidance given.
    | Oct. 13, 2015, 7:52 AM
  • Oct. 13, 2015, 7:32 AM
    • Enzo Biochem (NYSE:ENZ): FQ4 EPS of -$0.06 in-line.
    • Revenue of $25.7M (+3.2% Y/Y) beats by $1.1M.
    | Oct. 13, 2015, 7:32 AM
  • Jul. 22, 2015, 11:21 AM
    • Enzo Biochem (ENZ +1.9%) subsidiary Enzo Life Sciences settles its infringement case with Siemens Healthcare Diagnostics regarding U.S. Patent 7,064,197 covering viral load monitoring technology. Under the terms of the settlement agreement, Siemens will pay Enzo $9.5M upfront and up to $5M in licensing royalties over a five-year period.
    • This is one of 12 cases brought by Enzo against various companies. It is the second settlement. On July 6, Luminex (LMNX +1.5%) agreed to pay Enzo $7.1M.
    | Jul. 22, 2015, 11:21 AM
  • Jul. 6, 2015, 10:49 AM
    • Enzo Biochem (ENZ +0.3%) settles its dispute with Luminex (LMNX +0.8%) concerning the latter's alleged infringement of Enzo's U.S. Patent Nos. 6,992,180, 7.064,197 and 8,097,405. Luminex agrees to pay Enzon $7.1M to settle the matter.
    • Enzo's infringement suits against other companies are ongoing.
    | Jul. 6, 2015, 10:49 AM
  • Jun. 10, 2015, 2:05 AM
    • Enzo Biochem (ENZ +4.7%) FQ3 results: Revenues: $24M (unch); Gross Profit: $10.5M (+1.0%); Operating Loss: ($3M) (-650.0%); Net Loss: ($2.9M) (-480.0%); Loss Per Share: ($0.06) (-500.0%); Quick Assets: $14.4M (-17.7%).
    • No guidance given.
    | Jun. 10, 2015, 2:05 AM
  • Jun. 9, 2015, 4:18 PM
    • Enzo Biochem (NYSE:ENZ): FQ3 EPS of -$0.07 misses by $0.01.
    • Revenue of $23.99M (flat Y/Y) misses by $0.41M.
    | Jun. 9, 2015, 4:18 PM
  • Mar. 31, 2015, 5:36 PM
    | Mar. 31, 2015, 5:36 PM | 3 Comments
  • Mar. 16, 2015, 5:41 PM
    | Mar. 16, 2015, 5:41 PM
Company Description
Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.